Saturday 17 October 2026
Export PRME’s income statement to Excel — free account
Prime Medicine, Inc.
PRME Healthcare Biotechnology
Prime Medicine, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $4.6 million, up 55.3% from fiscal 2024. In the quarter to June 2026, revenue grew 3.50%, EPS grew 41.5% and free cash flow grew 4.40%, each against the same quarter a year earlier.
3.47
0.14
−3.88%
Follow PRME
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
|
+8 more TTM periods Free account |
(112.34%) | (146.81%) | (216.07%) | (373.29%) | |
| (54.98%) | (62.83%) | (63.69%) | (71.16%) | ||
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
(90.34%) | (122.34%) | (164.74%) | (228.61%) | |
Average Days of Receivables |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(0.72) | (1.12) | (0.90) | (0.88) | |
Free Cash Flow |
(115.09) | (167.09) | (158.74) | (156.85) | |
Capital Expenditures |
(6.03) | (4.53) | (2.32) | (0.80) | |
| Other line items | |||||
Cash ROIC |
(30.68%) | (55.97%) | (74.81%) | (116.29%) | |
Accounts Receivable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
2,677.45% | 3,467.96% | 3,821.99% | 3,589.52% | |
Selling, General and Administrative Expense of Revenue |
835.03% | 1,130.09% | 1,399.78% | 1,335.43% | |
Share Based Compensation of Revenue |
513.54% | 631.87% | 699.83% | 657.28% | |
Operating CF/Net income |
0.55 | 0.81 | 0.79 | 0.83 | |
Depreciation/Fixed assets |
0.27 | 0.26 | 0.28 | 0.31 | |
Capex/Depreciation |
(1.03) | (0.84) | (0.44) | (0.15) | |
Revenue per Share |
0.04 | 0.03 | 0.02 | 0.02 | |
Operating CF per Share |
(0.68) | (1.09) | (0.88) | (0.88) | |
Capex per Share |
(0.04) | (0.03) | (0.01) | 0.00 | |
Capex to Sales |
1.01 | 0.98 | 0.58 | 0.20 |
Columns are period end dates